Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Novasep Varicol high-performance continuous chromatography technology brings productivity gains in an Indian-based API commercial production.
Novasep wins approval to produce new molecular entity for US market.
The plant will enable Vietnam to domestically produce sorbitol, a sugar substitute it currently imports.
The new Highly Potent API (HPAPI) manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.